Eytan Stein, MD
Internal Medicine · New York, NYNPI 1114100047
Payments from drug & device makers
Across 554 payments — averaging $10,410 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Agios Pharmaceuticals, Inc.$1.1M
- Gilead$1.1M
- Servier Bioinnovation$926K
- Bristol Myers Squibb$541K
- Syndax Pharmaceuticals, Inc.$521K
- Eli Lilly$493K
- plus $1.2M from 25 others
Across 25 payments — averaging $2330.03 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Takeda Pharmaceuticals U.S.A., Inc.$34K
- Novartis$14K
- Bristol Myers Squibb$6K
- Servier Affaires Medicales$3K
- Servier Bioinnovation$2K
- Servier Pharmaceuticals LLC$104
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Agios Pharmaceuticals, Inc. | 63 | $1,072,480 |
| Gilead | 21 | $1,055,667 |
| Servier Bioinnovation | 57 | $926,440 |
| Bristol Myers Squibb | 43 | $540,555 |
| Syndax Pharmaceuticals, Inc. | 43 | $520,871 |
| Eli Lilly | 5 | $493,402 |
| Bayer | 58 | $321,139 |
| Amgen | 13 | $217,331 |
| Novartis | 24 | $165,456 |
| AbbVie | 57 | $116,783 |
| Servier Pharmaceuticals LLC | 41 | $66,197 |
| Daiichi Sankyo Inc. | 20 | $58,168 |
| Boehringer Ingelheim International GmbH | 7 | $39,078 |
| E.r. Squibb & Sons, L.L.C. | 6 | $29,921 |
| Seagen Inc. | 5 | $26,927 |
| Genentech USA, Inc. | 26 | $25,596 |
| Jazz Pharmaceuticals Inc. | 19 | $24,621 |
| AstraZeneca | 19 | $15,576 |
| LES Laboratoires Servier | 2 | $14,960 |
| Janssen Global Services, LLC | 3 | $9,933 |
| Astellas Pharma US Inc | 5 | $7,851 |
| Epizyme, Inc. | 3 | $3,400 |
| F. Hoffmann-la Roche AG | 2 | $3,090 |
| Daiichi Sankyo Europe GmbH | 1 | $2,903 |
| Janssen Scientific Affairs, LLC | 2 | $2,517 |
| Blueprint Medicines Corporation | 1 | $2,340 |
| Kyowa Kirin, Inc. | 1 | $1,200 |
| Astellas Pharma Global Development | 3 | $1,109 |
| Rigel Pharmaceuticals, Inc. | 1 | $1,028 |
| Servier Affaires Medicales | 2 | $730 |
| Beigene USA, Inc. | 1 | $23 |
How this compares
$5,767,290 in reported general payments places this provider in the 95th percentile of 9,771 internal medicine providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other internal medicine in New York
- Helena YuNew York$50.9M
- Neha KordeNew York$21.2M
- Karen AutioNew York$18.5M
- Ingo MellinghoffNew York$16.1M
- Gopakumar IyerNew York$12.4M
- Sally LauNew York$8.4M
- Maria RubinsteinNew York$6.3M
- Dana RathkopfNew York$6M
- James GreenwaldNew York$4.9M
- Claire FriedmanNew York$4.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.